KnowraBiosimilarLinked fromLinked fromThe 11 pages that link to Biosimilar, each with the reason it gives.All 11Broader topic 1Related 5Narrower topic 1Compared with 4Monoclonal antibodyRelated: Biosimilars can broaden access to established monoclonal antibody treatments.Pharmaceutical industryBroader topic: Biosimilars extend competition to complex medicines made from living systems.Generic drugCompared with: Biosimilars address comparable access goals but are not conventional generic drugs.Biologic therapyRelated: Biosimilars provide close alternatives to reference biologics after patent protections expire.Drug developmentCompared with: Biosimilar development compares a product with an existing biologic rather than starting from an unapproved candidate.Disease-modifying antirheumatic drugRelated: Biosimilars can offer alternatives to some biologic DMARDs while retaining the same treatment target.BiopharmaceuticalCompared with: Biosimilars are compared with a reference biopharmaceutical rather than treated as exact copies.BevacizumabRelated: Biosimilars provide alternatives to reference bevacizumab after regulatory approval.WHO Model List of Essential MedicinesRelated: Biosimilars can change the cost and availability of biological treatments on the list.QulastaNarrower topic: Biosimilar pegfilgrastim products provide alternatives to branded pegfilgrastim.Therapeutic antibodyCompared with: Biosimilars offer an alternative to the original antibody product after regulatory comparison.